Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03680859 · ClinicalTrials.gov registry record

Gastroparesis Registry 3

A clinical trial, sponsored by Johns Hopkins Bloomberg School of Public Health.

Completed
Registry status
406
Enrollment target

NCT03680859: Completed study, sponsored by Johns Hopkins Bloomberg School of Public Health.

NCT03680859 is a clinical trial that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 406 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03680859 has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.

COMPLETED
Registry status
406 participants
Enrollment target

Study Summary

The purpose of this study is to create a new registry of patients with gastroparesis in order to better understand the characteristics of patients with gastroparesis and follow how their condition changes over time. The data collected may improve the understanding of the condition to enable better diagnosis and treatment.

Primary Outcome

The outcome is assessed using the self-reported postprandial fullness/early satiety subscore, which is computed as the average of 4 scores for 4-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: stomach fullness, inability to finish a normal-sized meal, feeling excessively full after meals, and loss of appetite. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 48-weeks minus

Trial Details

FieldValue
Enrollment Target 406 participants
Start Date 2019-01-24
Est. Completion 2024-05-13

What the finished NCT03680859 record still lists

NCT03680859 is an observational study that tracks outcomes without assigning an intervention. The registered 406 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT03680859 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03680859 about?

NCT03680859 is a clinical study titled "Gastroparesis Registry 3". The purpose of this study is to create a new registry of patients with gastroparesis in order to better understand the characteristics of patients with gastroparesis and follow how their condition changes over time. The data collected may improve the understanding of the condition to enable better d...

What is the current status of trial NCT03680859?

This trial is currently completed. The enrollment target is 406 participants. The study started on 2019-01-24. Estimated completion is 2024-05-13.

Who is sponsoring clinical trial NCT03680859?

This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06223360 · 406 participants · Phase 2

    A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

  • NCT06411769 · 406 participants · NA

    Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas

  • NCT06585787 · 406 participants · Phase 3

    A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  • NCT06735534 · 407 participants · NA

    Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03680859, the US trial registry maintained by the National Library of Medicine. NCT03680859 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.